MODERN PRINCIPLES OF CLASSIFICATION, PROGNOSIS AND TREATMENT OF PRIMARY MYELODYSPLASTIC SYNDROMES
https://doi.org/10.51523/2708-6011.2011-8-1-6
Abstract
Article is devoted myelodysplastic syndromes (MDS). It is group malignant diseases of a bone marrow in which basis the pathology hаemopoetic stem cells, leading to infringement proliferations and differentiations of hаemopoetic cells - predecessors with their change morphological and functional properties. Development of ordering MDS by variants, in particular, new classification the WHO (2008) is described. The estimation prognostic parametrs and systems is spent. Modern sights at treatment MDS with the account are presented an individualization of therapy on the basis of prognostic factors. The characteristic of new medical products and the analysis of results of application of standard therapeutic schemes in various modes and combinations is given.
References
1. Bennet, J. M. Proposals for the classification of the myelodysplastic syndromes / J. M.Bennet, D. Catovsky, M. T. Daniel // British journal of hematology. - 1982. - Vol. 51. - P. 189-199.
2. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes / O. Kosmider [et al.] // Blood. - 2009. - Vol. 114, № 15. - P. 3285-3291.
3. Guidelines for the diagnosis and treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Nordic MDS Group / L. Kjeldsen [et al.] // Blood. - 2010. - № 5. - 43 p.
4. Myelodysplastic Syndromes / A. F. List [et al.] // Hematology. - 2004. - P. 297-317.
5. Myelodysplastic syndromes/neoplasms, overview / R. D. Brunning [et al.] // In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues / Ed by S. H. Swerdlow [et al.] // Lyon: IARC. - 2008. - Vol. 2. - P. 88-93.
6. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system / O. K. Weinberg [et al.] // Blood. - 2009. - Vol. 113. - P. 1906-1908.
7. Greenberg, P. International Scoring System for evaluating prognosis in myelodysplastic syndromes/ P. Greenberg [et al.] // Blood. - 1997. - Vol. 89. -P. 2079-2088.
8. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes / P. Bernasconi [et al.] // British Journal of Haematology. - 2007. - Vol. 137. - P.193-205.
9. Сравнительный анализ кариотипа пожилых больных миелодиспластическим синдромом и острым миелоидным лейкозом / С. В. Грицаев [и др.] // Клиническая онкогематология. - 2010. - Т. 3, № 2. - C. 114-118.
10. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group / W. R. Sperr [et al.] // Annals of Oncology. - 2010. - Vol. 21 (1). - P. 114-119.
11. Greenberg, P. L. Current therapeutic approaches for patients with myelodysplastic syndromes / P. L. Greenberg // British Journal of Haematology. - 2010. - Vol. 150, № 2. - P. 131-143.
12. Steensma, D. P. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies / D. P. Steensma, A. Tefferi // Leukemia Research. - 2003. - Vol. 27, № 2. - P. 95-120.
13. Савченко, В. Г. Программное лечение лейкозов / В. Г. Савченко, Е. Н. Паровичникова, В. Г. Исаев. - М., 2002. - C. 166-179.
14. Циклоспорин А в терапии больных рефрактерными анемиями и острыми малопроцентными лейкозами / А. В. Кохно [и др.] // Проблемы гематологии и переливания крови. - 2002. - № 1. - C. 44-45.
15. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment / T. M. Westers [et al.] // Blood. - 2010. - Vol. 115(9). - P. 1779-1784.
16. Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the eastern cooperative oncology group (E1996) / P. L. Greenberg [et al.] // Blood. - 2009. - Vol. 114. - P. 2393-2400.
17. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach / S. Mundle [et al.] // Cancer. - 2009. - Vol. 115(4). - P. 706-715.
18. Novel vitamin D3 analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D3, that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells / J. Hisatake [et al.] // Blood. - 2001. - Vol. 97. - P. 2427-2433.
19. Loaiza-Bonilla, A. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents / A. Loaiza-Bonilla, S. D. Gore, H. E. Carraway // Current Opinion on Hematology. - 2010. - Vol. 17(2). - P. 104-109.
20. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes / L. Shen [et al.] // Journal of Clinical Oncology. - 2010. - Vol. 28(4). - P. 605-613.
21. Клиническая эффективность дакогена при миелодиспластическом синдроме / А. К. Голенков [и др.] // Клиническая онкогематология. - 2008. - № 4. - C. 36-40.
22. Steensma, D. P. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes / D. P. Steensma, R. M. Stone // Hematology/Oncology Clinics of North America. - 2010. - Vol. 24(2). - P. 389-406.
23. Hematologic response to three alternative dosing schedules of Azacitidine in patients with myelodysplastic syndromes / R. M. Lyons [et al.] // Journal of Clinical Oncology. - 2009. - Vol. 27 (11). - P. 1850-1856.
24. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes / A. Giagounidis [et al.] // Annals of Hematology. - 2008. - Vol. 87. - P. 345-352.
25. Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a Randomized Phase 2 Trial by the Cancer and Leukemia Group B (CALGB 19803) / D. L. Grinblatt [et al.] // Cancer. - 2009. - Vol. 115(1). - P. 84-93.
26. Circulating CD33 and its clinical value in acute leukemia / A. Abdoola [et al.] // Experimental hematology. - 2010. - Vol. 38, № 6. - P. 462-471.
27. Pagel, J. Radioimmunotherapeutic approaches for leukemia: the past, present and future / J. Pagel // Cytotherapy. - 2008. - Vol. 10 (1). - P. 13-20.
28. Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation / A. Lauter [et al.] // British Journal of Haematology. - 2010. - Vol. 148 (6). - P. 910-917.
Review
For citations:
Klimkovich N.N. MODERN PRINCIPLES OF CLASSIFICATION, PROGNOSIS AND TREATMENT OF PRIMARY MYELODYSPLASTIC SYNDROMES. Health and Ecology Issues. 2011;(1):34-41. (In Russ.) https://doi.org/10.51523/2708-6011.2011-8-1-6
Views: 255
Email this article 